FDA approves Nobelpharma's HYFTOR(TM) (sirolimus topical gel) 0.2%

HYFTOR™ is the first topical treatment approved by the FDA for facial angiofibroma in individuals with tuberous sclerosis complex (TSC) 6 years and older BETHESDA, Md., April 4, 2022 -- (Healthcare Sales & Marketing Network) -- Nobelpharma America, LLC... Biopharmaceuticals, FDA Nobelpharma America, HYFTOR, sirolimus, facial angiofibroma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news